Evidence map›Paper›PMID 36285546›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset.

John M Sahrmann, Margaret A Olsen, Dustin Stwalley, Holly Yu, Erik R Dubberke

Open access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Patients, antibiotics andJAC-antimicrobial resistance · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Healthcare Costs ofOpen forum infectious diseases · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John M SahrmannDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Margaret A OlsenDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Dustin StwalleyDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Holly YuPfizer, Inc., Collegeville, Pennsylvania, USA.
Erik R DubberkeDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Washington University in St. Louis · USPfizer (United States) · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
NCATS NIH HHS UL1 TR002345
6 · The paper itself

Abstract

backgroundAlthough hospital-onset Clostridioides difficile infection (CDI) is associated with significant healthcare costs, the economic burden of CDI with onset in other facilities or the community has not been well studied.

methodsIncident CDI cases were identified using 2011-2017 Medicare fee-for-service data. Controls were randomly selected in a 4:1 ratio matching to the CDI case surveillance definition. Inverse probability of exposure weights were used to balance on measured confounders. One-, 3-, and 5-year cumulative costs attributable to CDI were computed using a 3-part estimator (parametric survival model and pair of 2-part models predicting costs separately in intervals where death did and did not occur).

resultsA total of 60 492 CDI cases were frequency-matched to 241 968 controls. One-, 3-, and 5-year adjusted attributable costs were highest for hospital-onset CDI at $14 257, $18 953, and $21 792, respectively, compared with hospitalized controls and lowest for community-associated CDI compared with community controls at $1013, $3161, and $6454, respectively. Adjusted 1-, 3-, and 5-year costs attributable to community-onset healthcare facility-associated CDI were $8222, $13 066, and $16 329 and for other healthcare facility-onset CDI were $5345, $6764, and $7125, respectively.

conclusionsEconomic costs attributable to CDI in elderly persons were highest for hospital-onset and community-onset healthcare facility-associated CDI. Although lower, attributable costs due to CDI were significantly higher in cases with CDI onset in the community or other healthcare facility than for comparable persons without CDI. Additional strategies to prevent CDI in the elderly are needed to reduce morbidity and healthcare expenditures.

Indexed as

Clostridioides difficileClostridium InfectionsCross InfectionAgedHealth Care CostsHumansMedicareRetrospective StudiesUnited Statesattributable costsClostridioides difficile infectionhealthcare costsMedicare data

Identifiers

PMID36285546
PMCPMC10226732
OpenAlexW4307339897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.